Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynektikSTU:A2P -1.47%94 EBITDA Margin % is 25.05% as of Jun. 2026, which is 67% above its 10-year median of 15.01. GuruFocus rates STU:A2P with a GF Score™ of 94/100 and a GF Value™ of €68.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Synektik ranks better than 85.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Synektik's EBITDA for the
three
months ended in Jun. 2026 was €17.1 Mil. Synektik's Revenue for the
three
months ended in Jun. 2026 was €68.4 Mil. Therefore, Synektik's EBITDA margin for the quarter that ended in Jun. 2026 was 25.05%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Synektik EBITDA Margin % Related Terms
Synektik EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Synektik's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:A2P vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Synektik's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Synektik's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synektik (STU:A2P) has a EBITDA Margin % of 25.05% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synektik and its competitors. This is 67% above median its historical median of 15.01. Over the past decade, Synektik's EBITDA Margin % has ranged from 4.43 to 26.35. According to the industry distribution chart, Synektik ranks #117 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 14.3%.
Is Synektik's EBITDA Margin % too high?
Synektik's current EBITDA Margin % of 25.05% is 67% above median its 10-year median of 15.01. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 26.35. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Synektik's value of 25.05% is 230% above this industry median. Based on the distribution chart, Synektik ranks #117 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synektik has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #117 out of 816 companies for EBITDA Margin %. This places Synektik in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.59. Synektik's value of 25.05% is 230% above this benchmark. Historically, Synektik's own EBITDA Margin % has ranged from 4.43 to 26.35 over the past decade. While the company's 10-year median is 15.01 vs. the industry median of 7.59, Synektik has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current EBITDA Margin % of 25.05% is 230% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synektik and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current EBITDA Margin % is 25.05%, which is 67% above median its own 10-year median of 15.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (STU:A2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €68.36, compared to a current price of €83.85 — trading 22.7% above its estimated fair value. The current EBITDA Margin % is 25.05%, which is 67% above median its 10-year median of 15.01 and 230% above the Medical Devices & Instruments industry median of 7.59. Synektik's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Synektik (STU:A2P), the current EBITDA Margin % is 25.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (STU:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €83.85 is trading 22.7% above its estimated GF Value™ of €68.36.
GuruFocus considers Synektik to be Modestly Overvalued.
Key valuation signals for STU:A2P:
EBITDA Margin %: 25.05% (67% above median its 10-year median of 15.01)
GF Value™: €68.36 vs. price of €83.85 (22.7% above fair value)
Industry Position: 230% above the Medical Devices & Instruments median (#117 of 816)
No single metric tells the full story. See the STU:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
94GF Score
Get the complete analysis for STU:A2P
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:A2P has been successfully added to your 
